Having trouble accessing articles? Reset your cache.

With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder.

Viela Bio Inc. (NASDAQ:VIE) will receive $30 million up front and is eligible for undisclosed milestones, plus additional payments it described as “based, in part, on

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers